Navigation Links
Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
Date:10/23/2008

Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Investors:

Joshua Gordon, M.D.

T: +1-201-946-0561,

E: investors@rosettagenomics.com;

Media:

Ron Kamienchick,

T: +1-646-509-1893,

E: media@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
2. Rosetta Genomics Reports Second Quarter 2008 Financial Results
3. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
4. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
5. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
6. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
7. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
8. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
9. /C O R R E C T I O N -- Rosetta Genomics Ltd/
10. Rosetta Genomics Reports First Quarter 2008 Financial Results
11. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 ... the addition of the  "Global Hormone Replacement ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone replacement ... a means of replacing hormones that are ... This type of therapy is usually initiated ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 /PRNewswire/ ... OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, ... Capital Market.  Immune previously traded on OTCQX®, the ... operated by OTC Markets Group. Logo - ... Immune Pharmaceuticals on the successful execution of its ...
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... phase 3 study at the 47th Annual Meeting of ... PA. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , ... Infectious Diseases, Chair of the Infection Prevention and Control ...
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading ... cells, announced today it will report financial results for the ... 5, 2009. , Company,s Conference Call and ... Thursday, November 5, 2009 at 2:00 PM Pacific (5:00 PM ...
... LAKE, N.J., Oct. 30 Eisai Inc. today announced ... with eribulin mesylate (E7389), discovered and developed by the ... cancer. , This global Phase III study, known as ... Versus E7389), was an open-label, randomized, parallel two-arm, multi-center ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 4
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... research finds life can persist in a cold, dark ... a team that examined waters and sediments from a ... found the extreme environment supports microbial ecosystems. , ... her colleagues has implications for life in other extreme ... The findings are published in the current edition of ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Medicine (BUSM) have for the first time identified a novel ... pathogen Neisseria gonorrhoeae , which is responsible for the ... was recently published online in the Journal of Bacteriology ... transmitted disease. N. gonorrhoeae is a pathogenic ...
... British Columbia study has found traces of the bacteria listeria ... UBC food microbiologist Kevin Allen tested a total of 40 ... from seven large chain stores and 10 small retailers in ... and fish jerky. The findings published in ...
... In 2009, when the United States fell into economic recession, ... 2008. In the power sector, however, the recession was ... of Engineering and Applied Sciences (SEAS) have shown that the ... from power generation that year was that a decrease in ...
Cached Biology News:Researchers identify novel pathway responsible for infection of a common STD pathogen 2Traces of listeria found in Vancouver ready-to-eat fish products: UBC study 2Reduction in US carbon emissions attributed to cheaper natural gas 2Reduction in US carbon emissions attributed to cheaper natural gas 3
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
Request Info...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
Anti-hamster Ig HRP detection kit...
Biology Products: